다올투자證 “한미약품, 비만 신약 가치와 후속 기술이전 기대… 목표가 72만원으로↑”
Read the full article on 조선일보 →KioskNews shows the publisher’s own headline, image, and summary — the full article always lives on their site, not ours.
Read the full article on 조선일보 →KioskNews shows the publisher’s own headline, image, and summary — the full article always lives on their site, not ours.
Pick a conversation — tap 💬 on any story